Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. (ACOR) Revenue
Annual & quarterly revenue history · segment & region breakdown
ACOR · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAcorda Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.12B, a decrease of 0.79% year-over-year from $0.12B in FY2023.
Revenue trend
2023 – 2004 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.12B | -$0.00B | -0.79% |
| 2022-12-31 | $0.12B | -$0.01B | -8.14% |
| 2021-12-31 | $0.13B | -$0.02B | -15.62% |
| 2020-12-31 | $0.15B | -$0.04B | -20.50% |
| 2019-12-31 | $0.19B | -$0.28B | -59.19% |
| 2018-12-31 | $0.47B | -$0.12B | -19.86% |
| 2017-12-31 | $0.59B | +$0.07B | +13.22% |
| 2016-12-31 | $0.52B | +$0.03B | +5.47% |
| 2015-12-31 | $0.49B | +$0.09B | +22.71% |
| 2014-12-31 | $0.40B | +$0.07B | +19.34% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Acorda Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Acorda Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Acorda Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ACOR revenue · 4 questionsACOR's trailing twelve-month (TTM) revenue is $0.12B. That is a decrease of 0.79% year-over-year from $0.12B in FY2023.
▸ Source: FMP · Acorda Therapeutics, Inc. SEC filings · GAAP · Acorda Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026